Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study

Autor: Carlos Blaisdell-Vidal, Hugo López-Gatell, Daniel Amado Carrillo-García, Santa Elizabeth Ceballos-Liceaga, Rogelio Pérez-Padilla, Sergio I. Valdés-Ferrer, Gustavo Reyes-Terán, Miguel García-Grimshaw, Laura E. Hernández-Vanegas, Roger A. Carrillo-Mezo, Juan Sierra-Madero, Guillermo Carbajal-Sandoval, José Luis Díaz-Ortega, Sergio Fragoso-Saavedra, Juan L. Mosqueda-Gómez, María del Mar Saniger-Alba, Noé Hernández-Valdivia, Antonio Arauz, Javier Andrés Galnares-Olalde, Isaac Núñez, José Luis Alomía-Zegarra, Anaclara Michel-Chávez, Alba Espino-Ojeda
Rok vydání: 2021
Předmět:
Zdroj: Clinical Immunology (Orlando, Fla.)
ISSN: 1521-6616
DOI: 10.1016/j.clim.2021.108786
Popis: mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform.
Databáze: OpenAIRE
Externí odkaz: